REVENUE RECOGNITION AND RELATED ALLOWANCES (Tables)

6 Months Ended

Jun. 30, 2018

Revenue Recognition [Abstract]

Disaggregation of Revenue

The following table depicts the disaggregation of revenue according to contract type as of:

	Three Months Ended				Six Months Ended
(in thousands)	June 30,   2018		June 30,  2017		June 30,   2018		June 30,   2017
Sales of generic pharmaceutical products	$	30,202	$	31,490	$	53,429	$	58,061
Sales of branded pharmaceutical products		10,530		11,671		27,125		19,711
Sales of contract manufactured products		1,679		1,529		2,624		3,322
Royalties from Licensing Agreements		4,769		-		10,151		-
Other(1)		88		74		422		298
Total net revenues	$	47,268	$	44,764	$	93,751	$	81,392

(1)Primarily includes laboratory services and royalties on sales of contract manufactured products

Schedule of Valuation and Qualifying Accounts Disclosure

The following table summarizes activity in the consolidated balance sheets for accruals and allowances for the six months ended June 30, 2018 and 2017, respectively:

(in thousands)	Accruals for Chargebacks, Rebates, Returns, and Other Allowances
										Administrative			Prompt
				Government						Fees and Other			Payment
	Chargebacks			Rebates			Returns			Rebates			Discounts
Balance at December 31, 2016	$	26,785		$	5,891		$	5,756		$	3,550		$	1,554
Accruals/Adjustments		88,973			5,110			5,220			10,646			3,842
Credits Taken Against Reserve		(83,757	)		(7,467	)		(3,418	)		(8,593	)		(3,448	)
Balance at June 30, 2017	$	32,001		$	3,534		$	7,558		$	5,603		$	1,948
Balance at December 31, 2017	$	28,230		$	7,930		$	8,274		$	5,226		$	1,834
Accruals/Adjustments		104,331			4,199			6,227			14,855			4,157
Credits Taken Against Reserve		(82,145	)		(6,873	)		(4,737	)		(13,365	)		(3,859	)
Balance at June 30, 2018	$	50,416		$	5,256		$	9,764		$	6,716		$	2,132